{
    "id": "be84225c-ae2c-42de-aa49-d88986b96dfa",
    "indications": "JADENU is an iron chelator indicated for the treatment of chronic iron overload due to blood transfusions in patients 2 years of age and older. ( 1.1 ) JADENU is indicated for the treatment of chronic iron overload in patients 10 years of age and older with non-transfusion-dependent thalassemia (NTDT) syndromes, and with a liver iron (Fe) concentration (LIC) of at least 5 mg Fe per gram of dry weight (Fe/g dw) and a serum ferritin greater than 300 mcg/L. ( 1.2 ) Limitations of Use: The safety and efficacy of JADENU when administered with other iron chelation therapy have not been established. ( 1.3 )",
    "contraindications": "Transfusional Iron Overload: Initial dose for patients with estimated glomerular filtration rate (eGFR) greater than 60 mL/min/1.73 m 2 is 14 mg per kg (calculated to nearest whole tablet or nearest whole sachet content for granules) once daily. ( 2.1 ) NTDT Syndromes: Initial dose for patients with eGFR greater than 60 mL/min/1.73 m 2 is 7 mg per kg (calculated to nearest whole tablet or nearest whole sachet content for granules) once daily. ( 2.2 ) See full prescribing information for information regarding monitoring, administration, and dose-reductions for organ impairment. ( 2.1 , 2.2 , 2.3 , 2.4 )",
    "warningsAndPrecautions": "JADENU 90 mg tablets are light blue in color, film-coated, oval biconvex tablets with beveled edges, debossed with ‘NVR’ on one side and ‘90’ on a slight upward slope in between two debossed curved lines on the other side. They are available in bottles of 30 tablets……………………………………………(NDC 0078-0654-15)\n                  JADENU 180 mg tablets are medium blue in color, film-coated, oval biconvex tablet with beveled edges, debossed with ‘NVR’ on one side and ‘180’ on a slight upward slope in between two debossed curved lines on the other side. They are available in bottles of 30 tablets……………………………………………(NDC 0078-0655-15)\n                  JADENU 360 mg tablets are dark blue in color, film-coated, oval biconvex tablet with beveled edges, debossed with ‘NVR’ on one side and ‘360’ on a slight upward slope in between two debossed curved lines on the other side. They are available in bottles of 30 tablets……………………………………………(NDC 0078-0656-15)\n                  Store JADENU tablets at 20°C - 25°C (68°F - 77°F); excursions are permitted to 15°C to 30°C (59°F to 86°F) [see USP Controlled Room Temperature]. Protect from moisture.\n                  JADENU Sprinkle 90 mg granules are white to almost white granules in sachet. They are available in cartons of 30 sachets……………………………………………(NDC 0078-0727-15)\n                  JADENU Sprinkle 180 mg granules are white to almost white granules in sachet. They are available in cartons of 30 sachets……………………………………………(NDC 0078-0713-15)\n                  JADENU Sprinkle 360 mg granules are white to almost white granules in sachet. They are available in cartons of 30 sachets……………………………………………(NDC 0078-0720-15)\n                  Store JADENU Sprinkle granules at 20°C to 25°C (68°F to 77°F); excursions are permitted between 15°C to 30°C (59°F to 86°F) [see USP Controlled Room Temperature]. Protect from moisture.",
    "adverseReactions": "JADENU is contraindicated in patients with:\n                  \n                     Estimated GFR less than 40 mL/min/1.73 m2 [see Dosage and Administration (2.5), Warnings and Precautions (5.1)];\n                     Poor performance status [see Warnings and Precautions (5.1, 5.3)];\n                     High-risk myelodysplastic syndromes  (this patient population was not studied and is not expected to benefit from chelation therapy);\n                     Advanced malignancies [see Warnings and Precautions (5.1, 5.3)];\n                     Platelet counts less than 50 x 109/L [see Warnings and Precautions (5.3, 5.4)]; \n                     Known hypersensitivity to deferasirox or any component of JADENU [see Warnings and Precautions (5.7), Adverse Reactions (6.2)].",
    "ingredients": [
        {
            "name": "DEFERASIROX",
            "code": "V8G4MOF2V9"
        },
        {
            "name": "CELLULOSE, MICROCRYSTALLINE",
            "code": "OP1R32D61U"
        },
        {
            "name": "CROSPOVIDONE",
            "code": "68401960MK"
        },
        {
            "name": "POVIDONE K30",
            "code": "U725QWY32X"
        },
        {
            "name": "MAGNESIUM STEARATE",
            "code": "70097M6I30"
        },
        {
            "name": "SILICON DIOXIDE",
            "code": "ETJ7Z6XBU4"
        },
        {
            "name": "POLOXAMER 188",
            "code": "LQA7B6G8JG"
        },
        {
            "name": "LACTOSE MONOHYDRATE",
            "code": "EWQ57Q8I5X"
        },
        {
            "name": "SODIUM LAURYL SULFATE",
            "code": "368GB5141J"
        }
    ],
    "organization": "Novartis Pharmaceuticals Corporation",
    "name": "Jadenu",
    "effectiveTime": "20250501"
}